Rekah Pharmaceutical Industry Ltd.

Tel Aviv Stock Exchange REKA.TA

Rekah Pharmaceutical Industry Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -22.55

Rekah Pharmaceutical Industry Ltd. Price to Earnings Ratio (P/E) is -22.55 on January 14, 2025, a -14.22% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Rekah Pharmaceutical Industry Ltd. 52-week high Price to Earnings Ratio (P/E) is -16.28 on June 10, 2024, which is 27.80% above the current Price to Earnings Ratio (P/E).
Rekah Pharmaceutical Industry Ltd. 52-week low Price to Earnings Ratio (P/E) is -81.47 on December 20, 2024, which is -261.23% below the current Price to Earnings Ratio (P/E).
Rekah Pharmaceutical Industry Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -20.29.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Tel Aviv Stock Exchange: REKA.TA

Rekah Pharmaceutical Industry Ltd.

CEO	Mr. Mordechai Elgrabli
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	30 Hamelach Street
Employees	427
Sector	Health Care
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.

Key trends

Past 5 years